

CITATION REPORT

List of articles citing

Acute myocardial infarction associated with sildenafil

DOI: 10.1016/s0140-6736(98)00015-4
Lancet, The, 1998, 352, 957-8.

Source: <https://exaly.com/paper-pdf/29210453/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
105	Acute myocardial infarction associated with sildenafil. <i>Lancet, The</i> , 1998 , 352, 1936-7	40	3
104	Acute myocardial infarction associated with sildenafil. <i>Lancet, The</i> , 1998 , 352, 1937	40	3
103	Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. 1999 , 17, 3444-9		67
102	Progress in Interventional Cardiology. 1999 , 12, 95-98		1
101	Molecular mechanisms of the effects of sildenafil (VIAGRA). 1999 , 34, 305-18		53
100	Sildenafil. 1999 , 25, 271-9		11
99	Is management of impotence with sildenafil changing clinical practice?. <i>Lancet, The</i> , 1999 , 353, 375-6	40	4
98	Viagra--after one year. 1999 , 54, 12-7		55
97	Indications and early results of sildenafil (Viagra) in erectile dysfunction. 1999 , 54, 1073-7		43
96	Comparative tolerability and efficacy of treatments for impotence. 1999 , 20, 133-46		16
95	Sildenafil and erectile dysfunction. 1999 , 22, 486-92		19
94	Drugs acting on the cerebral and peripheral circulations. 1999 , 22, 221-223		
93	Bibliography current world literature. 1999 , 6, 41-58		
92	Safety of sildenafil. 2000 , 10, 613-5		2
91	The cost-effectiveness of sildenafil. 2000 , 132, 933-7		56
90	What is Pharmacoepidemiology?. 1-15		
89	Erectile dysfunction, sildenafil and cardiovascular risk. 2000 , 172, 279-283		25

88	Hemodynamic effects of sildenafil in men with severe coronary artery disease. 2000 , 342, 1622-6	257
87	Sildenafil: clinical toxicology profile. 2000 , 38, 645-51	35
86	Acute myocardial infarction associated with Sildenafil (Viagra) ingestion. 2000 , 18, 353-5	7
85	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. 2000 , 55, 146-50	109
84	Should patients be given an initial low test dose of sildenafil?. 2000 , 23, 1-9	9
83	VIAGRA : IS IT A WONDER DRUG ?. 2001 , 57, 44-6	1
82	Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. 2001 , 58, 441-5	37
81	INTRACAVERNOSAL INJECTION OF SILDENAFIL CITRATE: MISAPPLICATION OF THE DRUG. 2001 , 165, 1218-1219	2
80	Intracerebral haemorrhage associated with sildenafil citrate. 2001 , 248, 141-2	37
79	Viagra: are anaesthetists rising to the challenge?. 2001 , 56, 91-3	
78	The Dutch cohort of sildenafil users: baseline characteristics. 2001 , 87, 648-53	5
77	A prospective study of conservatively managed acute urinary retention: prostate size matters. 2001 , 87, 904-5	3
76	Reply. 2001 , 87, 904-905	
75	Editor's comment on: "Press release: further research supports Viagra safety profile". 2001 , 87, 905-7; author reply 907-9	
74	Editor's comment on: "Press release: further research supports Viagra safety profile". 2001 , 87, 907; author reply 907-8	
73	Reply. 2001 , 87, 907-909	
72	5-Hydroxytryptamine-induced potentiation of cholinergic responses to electrical field stimulation in pig detrusor muscle. 2001 , 87, 904	1
71	Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunctional patients. 2001 , 13, 100-3	68

70	Sex, the heart, and sildenafil. 2001 , 26, 388-415		4
69	Is the sildenafil product information adequate to facilitate informed therapeutic decisions?. 2001 , 35, 337-42		
68	Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. 2001 , 22, 342-88		164
67	Pharmacological aspects of erectile dysfunction. 2002 , 89, 101-12		14
66	Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. 2002 , 287, 719-25		132
65	The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. 2002 , 40, 2006-12		120
64	A 4-year update on the safety of sildenafil citrate (Viagra). 2002 , 60, 67-90		188
63	Fatal overdosage with sildenafil citrate (Viagra): first report and review of the literature. 2002 , 21, 623-9		21
62	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88		25
61	Myocardial infarction following the combined recreational use of Viagra and cannabis. 2002 , 25, 133-4		43
60	Sildenafil and transient global amnesia. 2003 , 24, 145-6		15
59	Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. <i>European Urology</i> , 2003 , 43, 544-51	10.2	12
58	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. 2003 , 108, 239-44		124
57	Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62		77
56	A stimulatory role for cGMP-dependent protein kinase in platelet activation. 2003 , 112, 77-86		221
55	Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. 2003 , 41, 734-43		42
54	Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications. 2004 , 13, 332-5		
53	Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. 2004 , 164, 514-20		65

52	Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. 2004 , 93, 796-801	36
51	Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis. 2004 , 9, 228-33	5
50	Erectile Dysfunction. 2005 , 199-220	1
49	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. 2005 , 112, 2642-9	142
48	Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 ,	
47	Acute myocardial infarction after sildenafil citrate ingestion. 2005 , 39, 1362-4	8
46	Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. 2005 , 100, 267-73	129
45	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. 2005 , 4, 531-40	18
44	Male Sexual Function. 2006 , 1173-1194	1
43	Stroke--an adverse reaction to sildenafil. 2006 , 29, 165-7	8
42	Cardiovascular effects of phosphodiesterase 5 inhibitors. 2006 , 12, 3485-94	45
41	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86	52
40	Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. 2007 , 8, 965-74	16
39	[Acute myocardial infarction associated to the Sildenafil consumption. A case report and review of the literature]. 2007 , 31, 52-7	1
38	Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. 2007 , 150, 567-76	42
37	Pulmonary embolism after tadalafil ingestion. 2008 , 30, 610-2	6
36	The use of phosphodiesterase 5 inhibitors with concomitant medications. 2008 , 31, 799-808	49
35	The cardiovascular safety of tadalafil. 2008 , 7, 43-52	8

34	Physiology and pathophysiology of erection: consequences for present medical therapy of erectile dysfunction. 1999 , 31 Suppl 1, 59-64	2
33	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. 2009 , 3, 201-211	1
32	Phosphodiesterase 5 inhibitors: are they cardioprotective?. 2009 , 83, 204-12	29
31	The relationship between acute coronary syndrome and sildenafil. 2013 , 31, 1424.e1-3	2
30	Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats. 2013 , 3, 84-7	14
29	Effect of sildenafil citrate on the structure of rat liver. 2013 , 36, 991-1003	
28	Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis. 2015 , 69, 436-43	7
27	Sexual Dysfunction in Men and Women. 2016 , 785-830	1
26	What Is Pharmacoepidemiology?. 2019 , 1-26	7
25	Update of the position paper on arterial hypertension and erectile dysfunction. 2020 , 38, 1220-1234	9
24	What is Pharmacoepidemiology?. 1-22	1
23	Sexual Dysfunction in Men and Women. 2011 , 778-816	2
22	Drug-Induced Thrombophilic or Prothrombotic States: An Underestimated Clinical Problem That Involves Both Legal and Illegal Compounds. 2017 , 23, 775-785	8
21	Atrial fibrillation and continuous hypotension induced by sildenafil in an intermittent WPW syndrome patient. 1999 , 40, 827-30	16
20	The Effect of Vaginal Sildenafil on The Outcome of Assisted Reproductive Technology Cycles in Patients with Repeated Implantation Failures: A Randomized Placebo-Controlled Trial. 2020 , 13, 289-295	6
19	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. 2021 , 1	1
18	INTRACAVERNOSAL INJECTION OF SILDENAFIL CITRATE: MISAPPLICATION OF THE DRUG. 2001 , 1218-1219	
17	Pharmakologische Therapie der erektilen Dysfunktion. 2002 , 285-297	

16	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		
15	Oral Type 5 Phosphodiesterase Therapy for Male and Female Sexual Dysfunction. 2004 , 107-119		
14	External Lyogel Formulation of Prostaglandin E1 Ethyl Ester. 2004 , 34, 107-114		
13	Sildenafil. 2006 , 3133-3137		
12	Klinische epidemiologie. 2007 , 1-16		
11	Section I: Psychological Interventions. 2007 , 373-376		
10	DRUGS THAT ACT ON THE CEREBRAL AND PERIPHERAL ARTERIAL AND VENOUS CIRCULATIONS. 2009 , 431-448		
9	1 Klinische epidemiologie. 2010 , 15-33		
8	An unusual adverse effect of sildenafil citrate: acute myocardial infarction in a nitrate-free patient. 2012 , 2012,		4
7	Phosphodiesterase type V inhibitors. 2016 , 734-742		
6	Klinische epidemiologie. 2017 , 1-19		
5	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. <i>Current Vascular Pharmacology</i> , 2021 , 19, 301-312	3.3	2
4	Ocular safety of Viagra, (sildenafil citrate). <i>Transactions of the American Ophthalmological Society</i> , 1999 , 97, 115-25; discussion 125-8		29
3	Re: Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil with Survival in Men with Coronary Artery Disease. <i>European Urology</i> , 2021 , 81, 120-120	10.2	0
2	Unprescribed and unnoticed: Retrospective chart review of adverse events of interactions between antidepressants and over-the-counter drugs. 13,		0
1	Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease.		0